MDxHealth SA opened lower at $0.15, compared with its previous close of $0.15. In the last trading session, the stock traded between $0.14 and $0.15. It showed a downward intraday trend.
An investment of $100 made 5 years ago in MDxHealth SA is now worth
$ 0.13
Resulting in a loss of
$ 99.87 (99.87%)
Note: Past profits do not guarantee future returns.
Rating from 5 Analysts
Today's Change
$-0.01 (-3.75%)
Day High
$0.15
Day Low
$0.14
Day Open
$0.15
Prev Close
$0.15
Volume
12,26,538
1W Return
-11.32%
1M Return
-76.77%
3M Return
-68.24%
6M Return
-92.91%
1Y Return
-96.83%
Market Cap ($ Mn)
13
PE Ratio
-
PB Ratio
-
PEG Ratio
-
ROE
-
ROCE
-23.08%
EPS (TTM)
$-0.22
1 Week
-11.32%
1 Month
-76.77%
3 Months
-68.24%
6 Months
-92.91%
9 Months
-96.04%
BTIG downgrades MDxHealth from Buy to Neutral rating
BTIG analyst Mark Massaro downgraded MDxHealth. Rating changed from Buy to Neutral. No specific financial metrics cited in source.
24 days agoMDxHealth Q3FY27 Results: Revenue flat at $22.7M, guidance suspended
MDxHealth suspended full-year 2026 revenue guidance of $110–115 million. Q3 revenue from continuing operations was approximately $22.7 million, flat YoY. Tissue-based test volume declined 11% YoY to 11,232 tests. Liquid-based test volume rose to 11,792 from 4,600 in prior year. Sales force turnover cited as primary cause for revenue shortfall.
28 days agoLake Street maintains Buy on MDxHealth, cuts price target to $3
Lake Street keeps MDxHealth (NASDAQ: MDXH) at Buy but slashes the price target from $5 to $3. Analyst Thomas Flaten’s move suggests a more conservative valuation view while retaining confidence in the stock’s long-term prospects.
3mo agoMDxHealth revenue up 16% in Q2, stock surges on guidance affirmation
MDxHealth reported Q2 2026 revenue of $27.2 million, beating consensus estimates and marking a 16% YoY increase. Despite a miss on loss per share (18 cents vs 16 cents consensus), the stock surged 127% after management reaffirmed FY26 sales guidance of $110-$115 million. The company also completed the wind-down of its Resolve UTI business, removing a $10.4 million liability.
3mo agoMdxhealth gets time to Dec 28 to regain Nasdaq bid price compliance
Mdxhealth SA received a Nasdaq notification regarding non-compliance with the minimum bid price requirement. The company has 180 days, until December 28, 2026, to regain compliance by maintaining a closing bid price of US$1.00 for ten consecutive business days. Business operations remain unaffected, and the company may consider options such as a reverse stock split to meet the requirement.
4mo agoMDXHealth publishes Oxford GPS-ProMPT study in European Urology Oncology
MDXHealth announced the peer-reviewed publication of the Oxford GPS-ProMPT study in European Urology Oncology. The study showed patients with favorable GPS mdx scores achieved up to 100% freedom-from-failure in surgery and radiotherapy cohorts. These findings support the ongoing GPS-ProtecT study and aim to establish GPS mdx as a genomic classifier backed by randomized clinical trial evidence.
4mo ago| Stock | LTP | Change % | Market Cap | PE |
|---|---|---|---|---|
| $717.71 | -0.07% | $2,65,923.04M | 33.49 | |
| $235.31 | -0.34% | $1,65,547.88M | 38.52 | |
| $702.59 | +0.85% | $55,354.26M | 39.00 | |
| $176.95 | -0.52% | $49,887.34M | 30.34 | |
| $319.82 | +2.51% | $46,375.50M | - | |
| $470.90 | -0.97% | $46,282.88M | 104.98 | |
| $274.53 | -0.23% | $45,242.54M | 32.52 | |
| $1,749.01 | -0.14% | $34,787.81M | 31.52 | |
| $212.93 | -0.92% | $32,195.02M | 40.22 | |
| $372.23 | +0.36% | $30,225.08M | 27.72 | |
| $258.69 | +0.10% | $28,460.82M | 25.77 | |
| $154.78 | -0.37% | $20,939.57M | - |
An investment of $100 made 5 years ago in MDxHealth SA is now worth
$ 0.13
Resulting in a loss of
$ 99.87 (99.87%)
Note: Past profits do not guarantee future returns.
